 Effectiveness glibenclamide myocardial ischemic ventricular arrhythmias non-insulin-dependent diabetes mellitus Glibenclamide hypoglycemic sulfonylurea blocker adenosine triphosphatase-modulated potassium ion channels opening channels myocardial cells acute myocardial hypoxia responsible ischemic ventricular arrhythmias antiarrhythmic effects drug non-insulin-dependent diabetic patients coronary artery disease evidence Holter monitoring ventricular premature complexes ventricular tachycardia transient myocardial ischemia patients electrocardiographic monitoring number duration myocardial ischemic events frequency ventricular premature complexes ventricular tachycardia minute ischemia percentage ventricular premature complexes total ischemic beats patients groups group patients metformin placebo group patients glibenclamide fourteenth day patients underwent control monitoring crossover groups new Holter monitoring sequence end second phase indicate frequency ventricular premature complexes episodes nonsustained ventricular tachycardia transient myocardial ischemia number duration acute myocardial ischemic attacks spontaneous ventricular arrhythmias glibenclamide antiarrhythmic effect ventricular arrhythmias transient myocardial ischemia